[1]

[2]

SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.

[3]

LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.

[4]

YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.

[5]

XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.

[6]

CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.

[7]

. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.

[8]

. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.

[9]

[10]

YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.

[11]

DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.

[12]

GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.

[13]

. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.

[14]

. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.

[15]

. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

组别	例数	HbA（%）
β-地贫组	71	10.34±3.68
对照组	2 042	19.32±6.83

组别	例数	HbA（%）
β-地贫组	71	10.34±3.68
对照组	2 042	19.32±6.83

基因型	表型	例数	构成比（%）
β^IVS-Ⅱ-654/β^N	β⁺/β	23	32.4
β^CD41-42/β^N	β⁰/β	18	25.4
β^CD17/β^N	β⁰/β	9	12.7
β^-28/β^N	β⁰/β	6	8.5
β^CD71-72/β^N	β⁰/β	3	4.2
β^E/β^N	β⁺/β	2	2.8
β^Cap/β^N	β⁺/β	2	2.8
β^-43/β^N	β⁺/β	2	2.8
β^CD27-28/β^N	β⁰/β	2	2.8
β^-26/β^N	β⁺/β	2	2.8
β^-28/β^-28	β⁺/β⁺	1	1.4
β^CD41-42/β^IVS-Ⅱ-654	β⁺/β⁺	1	1.4
合计		71	100.0

基因型	表型	例数	构成比（%）
β^IVS-Ⅱ-654/β^N	β⁺/β	23	32.4
β^CD41-42/β^N	β⁰/β	18	25.4
β^CD17/β^N	β⁰/β	9	12.7
β^-28/β^N	β⁰/β	6	8.5
β^CD71-72/β^N	β⁰/β	3	4.2
β^E/β^N	β⁺/β	2	2.8
β^Cap/β^N	β⁺/β	2	2.8
β^-43/β^N	β⁺/β	2	2.8
β^CD27-28/β^N	β⁰/β	2	2.8
β^-26/β^N	β⁺/β	2	2.8
β^-28/β^-28	β⁺/β⁺	1	1.4
β^CD41-42/β^IVS-Ⅱ-654	β⁺/β⁺	1	1.4
合计		71	100.0

HbA临界值（%）	敏感性（%）	特异性（%）	约登指数
10.00	58.8	95.8	0.546
11.00	76.5	94.2	0.707
12.00	76.5	89.6	0.661
13.00	82.4	84.6	0.670
14.00	82.4	79.3	0.617

RichHTML

PDF (PC)

[1]	LIN M,WEN Y F,WU J R,et al.Hemoglobinopathy:molecular epidemiological characteristics and health effects on Hakka people in the Meizhou region,southern China[J]. PLoS One,2013,8(2):e55024.
[2]	LIN M,ZHONG T Y,CHEN Y G,et al.Molecular epidemiological characterization and health burden of thalassemia in Jiangxi Province,P. R. China[J]. PLoS One,2014,9(7):e101505.
[3]	罗秋月,秦丹卿,尹爱华,等. 毛细管电泳在新生儿β-地中海贫血筛查中的应用[J]. 广东医学,2014,35(10):1502-1505.
[4]	万志丹,黄湘,钟裕恒,等. 滤纸干血片毛细管电泳技术检测HbA在筛查新生儿β-地中海贫中的应用价值[J] . 检验医学,2017,32(12):1128-1131.
[5]	黄烁丹,张惠琴,邹婕,等. 新生儿干血斑β地中海贫血筛查方法的研究[J]. 中国实验诊断学,2015,19(4):582-586.